Kane BiotechKNBIF +5.19% EV-to-OCF is -2.94 as of Jun. 24, 2026. The stock has 6 warning signs investors should review. Among 1,415 Biotechnology companies, Kane Biotech ranks worse than 53% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Kane Biotech's Enterprise Value is $5.64 Mil.
Kane Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.92 Mil. Therefore, Kane Biotech's EV-to-OCF for today is -2.94.
The historical rank and industry rank for Kane Biotech's EV-to-OCF or its related term are showing as below:
KNBIF'
s EV-to-OCF Range Over the Past 10 Years
Min: -56.69 Med: -4.88 Max: -1.14
Current: -2.94
During the past 13 years, the highest EV-to-OCF of Kane Biotech was -1.14. The lowest was -56.69. And the median was -4.88.
KNBIF's EV-to-OCF is ranked worse than 53% of 1415
companies
in the Biotechnology industry
Industry Median: -3.47
vs KNBIF: -2.94
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kane Biotech's PE Ratio (TTM) for today is calculated as:
Kane Biotech's share price for today is $0.0215.
Kane Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kane Biotech EV-to-OCF Related Terms
Kane Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Kane Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kane Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Kane Biotech's EV-to-OCF falls into.
Kane Biotech's current Enterprise Value is $5.64 Mil.
Kane Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a EV-to-OCF of -2.94 as of Jun. 24, 2026. According to the industry distribution chart, Kane Biotech ranks #750 out of 1415 companies in the Biotechnology industry, placing it in the top 53%.
Is Kane Biotech's EV-to-OCF too high?
Kane Biotech's current EV-to-OCF is -2.94. Based on the distribution chart, Kane Biotech ranks #750 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint.
How does Kane Biotech's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #750 out of 1415 companies for EV-to-OCF. This places Kane Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Kane Biotech's current EV-to-OCF is -2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current EV-to-OCF of -2.94. The current EV-to-OCF is -2.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current EV-to-OCF is -2.94 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 